Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to $3.2 million.

  • Regenerative Medical Technology's Change in Accured Expenses rose 21382.14% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 4743.05%. This contributed to the annual value of $4.1 million for FY2024, which is 2027.53% up from last year.
  • Regenerative Medical Technology's Change in Accured Expenses amounted to $3.2 million in Q3 2025, which was up 21382.14% from $664998.0 recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Change in Accured Expenses ranged from a high of $3.2 million in Q3 2025 and a low of -$21378.0 during Q2 2021
  • In the last 5 years, Regenerative Medical Technology's Change in Accured Expenses had a median value of $834647.0 in 2022 and averaged $847357.8.
  • As far as peak fluctuations go, Regenerative Medical Technology's Change in Accured Expenses tumbled by 14529.62% in 2021, and later surged by 238637.85% in 2022.
  • Over the past 5 years, Regenerative Medical Technology's Change in Accured Expenses (Quarter) stood at $500921.0 in 2021, then dropped by 17.49% to $413290.0 in 2022, then surged by 111.96% to $875995.0 in 2023, then rose by 19.13% to $1.0 million in 2024, then soared by 205.31% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $664998.0 for Q2 2025, and $908279.0 during Q1 2025.